<?xml version="1.0" encoding="UTF-8"?>
<p>Along with the harrowing surge in COVID‐19 cases, the whole world is witnessing the emerging vulnerabilities of pharmaceutical supply chain.
 <xref rid="hpm3016-bib-0063" ref-type="ref">
  <sup>63</sup>
 </xref> Previous Pakistani evidences indicated major gaps in access to essential medicines in Pakistan driven by deficits in the pharmaceutical supply chain and ambiguous pharmaceutical regulations.
 <xref rid="hpm3016-bib-0038" ref-type="ref">
  <sup>38</sup>
 </xref>, 
 <xref rid="hpm3016-bib-0055" ref-type="ref">
  <sup>55</sup>
 </xref>, 
 <xref rid="hpm3016-bib-0056" ref-type="ref">
  <sup>56</sup>
 </xref>, 
 <xref rid="hpm3016-bib-0064" ref-type="ref">
  <sup>64</sup>
 </xref>, 
 <xref rid="hpm3016-bib-0065" ref-type="ref">
  <sup>65</sup>
 </xref> Unsurprisingly, due to sudden demand fluctuation, raw material availability issues and nontraditional distribution tactics several essential (such as antipyretic, analgesics and other flu and cough medicines) and life‐saving medicines, facemasks, sanitizers and other protective equipment are currently short or scarcely available at high prices.
 <xref rid="hpm3016-bib-0040" ref-type="ref">
  <sup>40</sup>
 </xref> Taking into account this scenario, it will be a great challenge for the Pakistani government to fulfill the medicinal product related needs of the population, especially after the discovery of COVID‐19 treatment and vaccination. Additionally, lack of access to basic medicinal products may also have severe consequences for patients with other communicable and noncommunicable diseases.
</p>
